Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$1.00 USD
-0.04 (-3.85%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.01 +0.01 (1.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 3 | 28 | 7 | 1 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 1 | 0 | 0 |
Total Current Assets | 5 | 5 | 29 | 8 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 12 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5 | 6 | 29 | 8 | 32 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 4 | 2 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 2 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 1 | 2 |
Total Current Liabilities | 6 | 8 | 7 | 5 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 8 | 7 | 5 | 35 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 110 | 89 | 84 | 40 | 72 |
Retained Earnings | -110 | -91 | -62 | -37 | -75 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 0 | -3 | 22 | 3 | -3 |
Total Liabilities & Shareholder's Equity | 5 | 6 | 29 | 8 | 32 |
Total Common Equity | 0 | -3 | 22 | 3 | -3 |
Shares Outstanding | 1.70 | 0.20 | 0.20 | 0.00 | 0.00 |
Book Value Per Share | -0.14 | -12.70 | 111.30 | 3.02 | -3.15 |
Fiscal Year End for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 4 | 3 | 2 | 7 |
Receivables | 1 | 0 | 0 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 2 | 2 |
Total Current Assets | 5 | 5 | 5 | 5 | 10 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6 | 6 | 5 | 5 | 10 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 3 | 3 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 3 | 3 | 6 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 117 | 114 | 114 | 110 | 110 |
Retained Earnings | -115 | -111 | -111 | -110 | -107 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 3 | 3 | 0 | 3 |
Total Liabilities & Shareholder's Equity | 6 | 6 | 5 | 5 | 10 |
Total Common Equity | 3 | 3 | 3 | 0 | 3 |
Shares Outstanding | 5.20 | 3.10 | 3.00 | 1.70 | 1.70 |
Book Value Per Share | 0.50 | 0.98 | 0.86 | -0.14 | 2.01 |